


KGP591

Cat. No.:	HY-155249
CAS No.:	3018962-69-8
Molecular Formula:	C ₂₄ H ₂₁ NO ₅
Molecular Weight:	403.43
Target:	Microtubule/Tubulin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	KGP591 is a tubulin polymerization inhibitor (IC ₅₀ 0.57 μM). KGP591 induces significant G2/M stagnation, inhibits cell migration, disrupts microtubule structure and cell morphology in MDA-MB-231 cells. KGP591 shows antitumor activity in orthotopic model of kidney cancer (RENCA) ^[1] .																
In Vitro	<p>KGP591 (100 nM, 72 h) inhibits migration and proliferation in MDA-MB-231 cells^[1].</p> <p>KGP591 (100 nM, 30 min) induces microtubule disruption in MDA-MB-231 cells^[1].</p> <p>KGP591 (200 nM, 48 h) shows G2/M cell cycle arrest in MDA-MB-231 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Migration Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDA-MB-231 cells</td> </tr> <tr> <td>Concentration:</td> <td>100 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Decreased in wound width in cells and remained largely open.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDA-MB-231 cells</td> </tr> <tr> <td>Concentration:</td> <td>200 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Had an arrest of MDA-MB-231 cells at G2/M of the cell cycle.</td> </tr> </table>	Cell Line:	MDA-MB-231 cells	Concentration:	100 nM	Incubation Time:	72 h	Result:	Decreased in wound width in cells and remained largely open.	Cell Line:	MDA-MB-231 cells	Concentration:	200 nM	Incubation Time:	48 h	Result:	Had an arrest of MDA-MB-231 cells at G2/M of the cell cycle.
Cell Line:	MDA-MB-231 cells																
Concentration:	100 nM																
Incubation Time:	72 h																
Result:	Decreased in wound width in cells and remained largely open.																
Cell Line:	MDA-MB-231 cells																
Concentration:	200 nM																
Incubation Time:	48 h																
Result:	Had an arrest of MDA-MB-231 cells at G2/M of the cell cycle.																
In Vivo	<p>Phosphate prodrug KGP618 (150 mg/kg, subcutaneous injection, 24 h) for KGP591 shows tumor-selective vascular disrupting agents (VDA) efficacy in BALB/c mice with RENCA-luc xenograft^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>RENCA-luc xenograft in BALB/c mice^[1]</td> </tr> </table>	Animal Model:	RENCA-luc xenograft in BALB/c mice ^[1]														
Animal Model:	RENCA-luc xenograft in BALB/c mice ^[1]																

Dosage:	150 mg/kg
Administration:	Subcutaneous Injection
Result:	Caused significant reduction of Bio-Layer Interferometry (BLI) signal occurred within 2.5 h. Showed necrosis and severe hemorrhage in RENCA tumor tissue.

REFERENCES

[1]. Maguire CJ, et al. Synthesis and biological evaluation of structurally diverse α -conformationally restricted chalcones and related analogues. Medchemcomm. 2019 Jun 4;10(8):1445-1456.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA